Anti-inflammatory compositions, and uses thereof
A gut microbiome may be modulated in a patient in need thereof, by administering a composition comprising 3-O-acetyl-11-keto-b-boswellic acid (AKBA) or an extract of Boswellia serrata comprising from 30% to 90% AKBA to the patient; wherein the composition is administered at a dose sufficient to change the ratio between a first organism in the gut microbiome and a second organism in the gut microbiome, compared to a subject not treated with the composition. Modulation of the gut microbiome with AKBA may be used to treat allergic pulmonary inflammation in the patient. Modulation of the gut microbiome with AKBA may be used to maintain diversity and/or increase a percentage of Bifidobacterium pseudolongum in the gut microbiome of the patient. The composition may further comprise a lyophilized probiotic bacteria. The composition may be administered in combination with a second composition comprising a lyophilized probiotic bacteria.
1 . A method of treating a patient in need thereof by:
modulating a gut microbiome in the patient,
maintaining diversity in the gut microbiome of the patient, and/or
increasing a percentage of Bifidobacterium in the gut microbiome of the patient;
wherein the method comprises:
administering a composition comprising 3-O-acetyl-11-keto-β-boswellic acid (AKBA) or an extract of Boswellia serrata comprising from 30% to 90% AKBA to the patient;
wherein the composition is administered at a dose sufficient to:
increase levels of a first organism in the gut microbiome in comparison to a subject not treated with the composition, wherein the first organism is selected from the group consisting of at least one of:
a. a member of a genus selected from the group consisting of Lactiplantibacillus, Lacticaseibacillus, and Turicibacter ; and
b. Bifidobacterium pseudolongum ; and
decrease levels of a second organism in the gut microbiome in comparison to the subject not treated with the composition, wherein the second organism is selected from the group consisting of at least one member of a genus selected from the group consisting of Hyphomicrobium, Solirubrobacter and Steroidobacter.
2 . The method of claim 1 , wherein the method involves maintaining diversity and/or increasing a percentage of Bifidobacterium in the gut microbiome of the patient in need thereof, comprising:
administering a composition comprising 3-O-acetyl-11-keto-β-boswellic acid (AKBA) or an extract of Boswellia serrata comprising from 30% to 90% AKBA to the patient;
wherein the composition is administered at a dose sufficient to increase the percentage of Bifidobacterium pseudolongum in the gut microbiome, compared to a subject not treated with the composition.
3 . The method of claim 2 , wherein the composition comprises AKBA or the extract of Boswellia serrata in combination with a live or lyophilized probiotic bacteria.
4 . The method of claim 2 , wherein the method further comprises administering a second composition comprising a live or lyophilized probiotic bacteria.
5 . The method of claim 1 , wherein the method involves increasing a percentage of Bifidobacterium pseudolongum in a gut of a patient in need thereof, wherein the method comprises administering the extract of Boswellia serrata , wherein the extract of Boswellia serrata comprises a therapeutically effective amount of Boswellia serrata gum resin comprising boswellic acids.
6 . A method of modulating a gut microbiome of a patient comprising:
administering a composition comprising 3-O-acetyl-11-keto-b-boswellic acid (AKBA) or an extract of Boswellia serrata comprising from 30-90% AKBA to the patient,
wherein the composition is administered at a dose sufficient to:
increase levels of a first organism in the gut microbiome in comparison to a subject not treated with the composition, wherein the first organism is selected from the group consisting of:
a. a member of a genus selected from the group consisting of Lactiplantibacillus, Lacticaseibacillus, and Turicibacter ; and
b. Bifidobacterium pseudolongum ; and
decrease levels of a second organism in the gut microbiome in comparison to a subject not treated with the composition, wherein the second organism is selected from the group consisting of a member of a genus selected from the group consisting of Hyphomicrobium, Solirubrobacter and Steroidobacter.
7 . The method of claim 6 , wherein the first organism is the member of the genus selected from the group consisting of Lactiplantibacillus, Lacticaseibacillus, and Turicibacter.
8 . The method of claim 6 , wherein the first organism is Bifidobacterium pseudolongum.
9 . The method of claim 6 , wherein the composition comprises AKBA or the extract of Boswellia serrata in combination with a live or lyophilized probiotic bacteria.
10 . The method of claim 6 , wherein the method further comprises administering a second composition comprising a live or lyophilized probiotic bacteria.
11 . The method of claim 6 , wherein the composition comprises AKBA or the extract of Boswellia serrata in combination with a live or lyophilized probiotic bacteria; and the probiotic bacteria is Bifidobacterium pseudolongum.